- Home
- MIST vs CRBU Comparison
MIST vs CRBU Comparison
Compare MIST & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MIST | CRBU |
|---|---|---|
| Founded | 2003 | 2011 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 131.3M | 145.8M |
| IPO Year | 2019 | 2021 |
Fundamental Metrics
Financial Performance| Metric | MIST | CRBU |
|---|---|---|
| Price | $1.04 | $1.68 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | $8.00 | ★ $10.75 |
| AVG Volume (30 Days) | ★ 1.7M | 1.0M |
| Earning Date | 05-13-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.64 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $2,915.14 | $1.63 |
| Revenue Next Year | N/A | $10.93 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.00 | $1.38 |
| 52 Week High | $3.06 | $3.53 |
Technical Indicators
Market Signals| Indicator | MIST | CRBU |
|---|---|---|
| Relative Strength Index (RSI) | 39.32 | 52.26 |
| Support Level | $1.01 | $1.40 |
| Resistance Level | $1.42 | $1.73 |
| Average True Range (ATR) | 0.07 | 0.07 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 7.41 | 69.65 |
Price Performance
Historical ComparisonAbout MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of cardiovascular medicines. Its approved product CARDAMYST (etripamil) nasal spray is available in the United States and is the self-administered treatment for use by patients anywhere, anytime an attack of PSVT occurs. It operates in single segment.
About CRBU Caribou Biosciences Inc.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.